Incannex Healthcare Ltd (IXHL) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors

NEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq:...

Form 8-K - Current report

Form RW - Registration Withdrawal Request

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier...

Form 8-K - Current report

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no...

Form 8-K - Current report

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL...

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare...